GPC3 and hepatocellular carcinoma: Through physical enrichment by Labyrinth chip and immunofluorescence staining using GPC3, CD44, and HepPar-1 antibodies, CTCs were detected in 37/42 (88.1%) of HCC patients, and CD44+ CTCs were identified in 30/42 (71.4%) of HCC patients (93).